Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sugen (SUGN) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Tauscher who wrote (408)	4/22/1999 9:57:00 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 550

Thanks Steve. It is clear that SUGN will go with their own path, without big pharma as partner (IN EU) for oncology drugs. They sound very confidence in this approach, and I hope that they can finish what they started. SUGEN EU is not only for drug marketing. They will be involved in EU clinical trials and EU regulatory work. It seams that they have secured finance for SUGEN EU, but DK didn't want to talk about this. EU show growing interest for start-up or development stage bts, so EU public offering or/and VC investment is one option, beside finance support from regional marketing partner. Based on SU5416 promising data in early trials I like SUGEN EU idea very much. Interesting that there was no analyst from large bt IH (no questions, I do not now for their presence), only two retail investors had few questions. And, DK (CFO) was very open for discussion. No interest, or everybody is hiding??? Miljenko